



**Supplemental Figure 1. Strength of TCR signaling during activation and re-stimulation of CD8 T cells.** Wild-type, Fas- (*lpr*), or FasL-deficient (*glid*) CD8<sup>+</sup> OT-I cells were activated in the presence of WT, *lpr*, or *glid* BM-DCs loaded with varying concentrations of the ovalbumin-derived peptide SIINFEKL (0.1-1000 nM). After 48 hours (activation), CD8 expression levels were quantified by flow cytometry in an aliquot of the cells. The rest were placed in a new plate with fresh BM-DCs (in the presence of SIINFEKL). CD8 expression was reevaluated after 72 hours (120 h re-stimulation). Percentage of CD8<sup>+</sup> cells (left) or CD8 expression per cell (mean fluorescence intensity; MFI; middle), or TCR-V $\alpha$ 2 expression per cell (right), on OT-I cells is shown.

**Supplemental Table 1. Flow cytometry antibodies**

Target	Fluorochrome	Clone	Catalog number and company
CD8a	PE	53-6.7	50-0081, Tonbo Biosciences
	PerCP-Cyanine5.5	53-6.7	65-0081, Tonbo Biosciences
	FITC	53-6.7	35-0081, Tonbo Biosciences
	redFluor 710	53-6.7	80-0081, Tonbo Biosciences
TCR V $\alpha$ 2	FITC	B20.1	127805, BioLegend
	Pacific Blue	B20.1	127816, BioLegend
	PE	B20.1	127808, BioLegend
TCR V $\beta$ 5	PE/Cyanine7	MR9-4	139508, BioLegend
CD44	violetFluor 450	IM7	75-0441, Tonbo Biosciences
	FITC	IM7	35-0441, Tonbo Biosciences
CD45.1	APC-Cyanine 7	A20	25-0453, Tonbo Biosciences
	FITC	A20	35-0453, Tonbo Biosciences
	Brilliant Violet 605	A20	110738, BioLegend
CD45.2	APC-Cyanine 7	104	25-0454, Tonbo Biosciences
	APC	N418	20-0114, Tonbo Biosciences
	violetFluor 450	104	75-0454, Tonbo Biosciences
CD11c	APC	N418	17-0114-81, eBiosciences
I-A/I-E	Pacific Blue	M5/114.15.2	107620, BioLegend
Fas	APC	15A7	17-0951-82, Invitrogen
FasL	PE	MFL3	106606, BioLegend